Evidence map›Paper›PMID 28753595›Full record

Trial reportBlood cancer journal2017

Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.

H-A Hou, J-W Lu, T-Y Lin, X C-H Tsai, W-C Chou, C-C Lin, Y-Y Kuo, C-Y Liu, M-H Tseng, Y-C Chiang and 5 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. CEBPA-Regulated Expression ofFoods (Basel, Switzerland) · 2023
    Article
  4. Zebrafish: a convenient tool for myelopoiesis research.Cell regeneration (London, England) · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.International journal of environmental research and public health · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

H-A HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
J-W LuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
T-Y LinDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
X C-H TsaiDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.ORCID 0000-0002-4174-8766
W-C ChouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
C-C LinDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Y-Y KuoGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
C-Y LiuDepartment of Nursing, Biostatistics Consulting Laboratory, National Taipei College of Nursing, Taipei, Taiwan, ROC.
M-H TsengDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Y-C ChiangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Y-L PengDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
J-L TangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Z GongDepartment of Biological Sciences, National University of Singapore, Singapore, Singapore.
L-I LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
H-F TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
National Taiwan University Hospital · TWNational Taiwan University · TWNational University of Singapore · SGNational Taipei University of Nursing and Health Science · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suppressor of cytokine signaling 1 (SOCS1) protein, which encodes a member of signal transducers and activators of transcription-induced inhibitors, takes part in a negative regulation of cytokine signaling. The mechanism of SOCS1 in tumor carcinogenesis is complex and there have been no studies concerning the clinic-biologic implication of SOCS1 expression in acute myeloid leukemia (AML). Here, we first identified that higher bone marrow (BM) SOCS1 expression was closely associated with older age, FLT3-ITD, NPM1 and DNMT3A mutations, but negatively correlated with CEBPA mutation in patients with de novo AML. Compared to patients with lower SOCS1 expression, those with higher expression had lower complete remission rates and shorter overall survival. Further, higher expression of SOCS1 in the BM was an independent unfavorable prognostic factor irrespective of age, white blood cell, cytogenetics and gene mutations. Next, we generated zebrafish model overexpressing SOCS1 by spi1 promoter, which showed kidney marrow from adult SOCS1 zebrafish had increased myelopoiesis, myeloid progenitors and the kidney or spleen structure were effaced and distorted, mimicking leukemia phenotype. The SOCS1/FLT3-ITD double transgenic fish could further facilitate the leukemic process. The results indicate SOCS1 plays an important role in AML and its higher expression serves as a new biomarker to risk-stratify AML patients.

Indexed as

AdolescentAdultAgedAged, 80 and overAnimalsAnimals, Genetically ModifiedBiomarkers, TumorDisease-Free SurvivalHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm ProteinsNucleophosminSuppressor of Cytokine Signaling 1 ProteinSurvival RateBiomarkers, TumorNeoplasm ProteinsNPM1 protein, humanNucleophosminsocs1a protein, zebrafishSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinZebrafish Proteins

Identifiers

PMID28753595
PMCPMC5549259
OpenAlexW2741315569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.